<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39308511</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1555-3906</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Oncology research</Title><ISOAbbreviation>Oncol Res</ISOAbbreviation></Journal><ArticleTitle>mRNA vaccines: a new era in vaccine development.</ArticleTitle><Pagination><StartPage>1543</StartPage><EndPage>1564</EndPage><MedlinePgn>1543-1564</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.32604/or.2024.043987</ELocationID><Abstract><AbstractText>The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body's innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized and adaptive nature of mRNA vaccines holds immense potential for addressing the heterogeneity of cancer and tailoring treatments to individual patients. Recent breakthroughs in the development of mRNA vaccines, exemplified by the success of COVID-19 vaccines, have accelerated their application in oncology. The mRNA platform's versatility allows for the rapid adaptation of vaccine candidates to various cancer types, presenting an agile and promising avenue for therapeutic intervention. Clinical trials of mRNA cancer vaccines have demonstrated encouraging results in terms of safety, immunogenicity, and efficacy. Pioneering candidates, such as BioNTech's BNT111 and Moderna's mRNA-4157, have exhibited promising outcomes in targeting melanoma and solid tumors, respectively. These successes underscore the potential of mRNA vaccines to elicit robust and durable anti-cancer immune responses. While the field holds great promise, challenges such as manufacturing complexities and cost considerations need to be addressed for widespread adoption. The development of scalable and cost-effective manufacturing processes, along with ongoing clinical research, will be pivotal in realizing the full potential of mRNA cancer vaccines. Overall, mRNA cancer vaccines represent a cutting-edge therapeutic approach that holds the promise of transforming cancer treatment. As research progresses, addressing challenges and refining manufacturing processes will be crucial in advancing these vaccines from clinical trials to mainstream oncology practice, offering new hope for patients in the fight against cancer.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>Shubhra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Pharmacy &amp; Medical Sciences, Gold Coast campus, Griffith University, Brisbane, QLD-4222, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Health Institute Queensland (MHIQ), Gold Coast Campus, Griffith University, Brisbane, QLD-4215, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>School of Pharmacy &amp; Medical Sciences, Gold Coast campus, Griffith University, Brisbane, QLD-4222, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Health Institute Queensland (MHIQ), Gold Coast Campus, Griffith University, Brisbane, QLD-4215, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Good</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Allied Health, Australian Catholic University, Brisbane, QLD-4014, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Ming Q</ForeName><Initials>MQ</Initials><AffiliationInfo><Affiliation>School of Pharmacy &amp; Medical Sciences, Gold Coast campus, Griffith University, Brisbane, QLD-4222, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Menzies Health Institute Queensland (MHIQ), Gold Coast Campus, Griffith University, Brisbane, QLD-4215, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncol Res</MedlineTA><NlmUniqueID>9208097</NlmUniqueID><ISSNLinking>0965-0407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="Y">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019496" MajorTopicYN="Y">Cancer Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="Y">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer immunotherapy</Keyword><Keyword MajorTopicYN="N">Delivery system</Keyword><Keyword MajorTopicYN="N">Immune checkpoint</Keyword><Keyword MajorTopicYN="N">Preventive &amp; therapeutic vaccine</Keyword><Keyword MajorTopicYN="N">mRNA</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest to report regarding the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39308511</ArticleId><ArticleId IdType="pmc">PMC11413818</ArticleId><ArticleId IdType="doi">10.32604/or.2024.043987</ArticleId><ArticleId IdType="pii">43987</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kumari, N., Siddhanta, K., Panja, S., Joshi, V., Jogdeo, C.et al. (2023). Oral delivery of nucleic acid therapies for local and systemic action. Pharmaceutical Research , 40(1), 107–122. 10.1007/s11095-022-03415-7;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-022-03415-7</ArticleId><ArticleId IdType="pmc">PMC9589866</ArticleId><ArticleId IdType="pubmed">36271204</ArticleId></ArticleIdList></Reference><Reference><Citation>Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I.et al. (2021). The limitless future of RNA therapeutics. Frontiers in Bioengineering and Biotechnology , 9, 628137. 10.3389/fbioe.2021.628137;</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2021.628137</ArticleId><ArticleId IdType="pmc">PMC8012680</ArticleId><ArticleId IdType="pubmed">33816449</ArticleId></ArticleIdList></Reference><Reference><Citation>de Smet, M. D., Meenken, C. J., van den Horn, G. J., (1999). Fomivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocular Immunology Inflammation , 7(3–4), 189–198. 10.1076/ocii.7.3.189.4007;</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/ocii.7.3.189.4007</ArticleId><ArticleId IdType="pubmed">10611727</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang, E., Liu, X., Li, M., Zhang, Z., Song, L.et al. (2022). Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy , 7(1), 94. 10.1038/s41392-022-00950-y;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00950-y</ArticleId><ArticleId IdType="pmc">PMC8940982</ArticleId><ArticleId IdType="pubmed">35322018</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo, G. T., Mahiny, A. J., Vlatkovic, I. (2022). COVID-19 mRNA vaccines: Platforms and current developments. Molecular Therapy , 30(5), 1850–1868. 10.1016/j.ymthe.2022.02.016;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.016</ArticleId><ArticleId IdType="pmc">PMC8856755</ArticleId><ArticleId IdType="pubmed">35189345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamous, Y. F., Alhomoud, D. A. (2023). The safety and effectiveness of mRNA vaccines against SARS-CoV-2. Cureus , 15(9), e45602. 10.7759/cureus.45602;</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.45602</ArticleId><ArticleId IdType="pmc">PMC10588549</ArticleId><ArticleId IdType="pubmed">37868494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zogg, H., Singh, R., Ro, S. (2022). Current advances in RNA therapeutics for human diseases. International Journal Molecular Science , 23(5), 2736. 10.3390/ijms23052736;</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052736</ArticleId><ArticleId IdType="pmc">PMC8911101</ArticleId><ArticleId IdType="pubmed">35269876</ArticleId></ArticleIdList></Reference><Reference><Citation>Goleij, P., Babamohamadi, M., Rezaee, A., Sanaye, PM., Tabari, M. A. K., et al. . (2024). Types of RNA therapeutics. Progress in Molecular Biology and Translational Science, 203, 41–63. 10.1016/bs.pmbts.2023.12.022;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pmbts.2023.12.022</ArticleId><ArticleId IdType="pubmed">38360005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess, P. R., Boczkowski, D., Nair, S. K., Snyder, D., Gilboa, E. (2006). Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunology, Immunotherapy , 55(6), 672–683. 10.1007/s00262-005-0064-z;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-005-0064-z</ArticleId><ArticleId IdType="pmc">PMC11030883</ArticleId><ArticleId IdType="pubmed">16133108</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed, Y. Y. (2023). Nedosiran: First approval. Drugs , 83(18), 1729–1733. 10.1007/s40265-023-01976-4;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-023-01976-4</ArticleId><ArticleId IdType="pmc">PMC10803381</ArticleId><ArticleId IdType="pubmed">38060091</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, J. K. (2023). Eli Lilly RNA drug lowered heart disease risk biomarker for nearly a year in phase I trial. https://www.precisionmedicineonline.com/cardiovascular-disease/eli-lilly-rna-drug-lowered-heart-disease-risk-biomarker-nearly-year-phase-i
(accessed on 21/12/2023).</Citation></Reference><Reference><Citation>Gareri, C., Polimeni, A., Giordano, S., Tammè, L., Curcio, A.et al. (2022). Antisense oligonucleotides and small interfering RNA for the treatment of dyslipidemias. Journal of Clincal Medicine , 11(13), 3884;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9267663</ArticleId><ArticleId IdType="pubmed">35807171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis [press release]. AstraZeneca. https://www.placera.se/placera/pressmeddelanden/2023/12/22/astrazeneca-wainua-eplontersen-granted-first-ever-regulatory-approval-in-the-us-for-the-treatment-of-dults-with-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis.html
(accessed on 21/12/2023).</Citation></Reference><Reference><Citation>Holm, A., Løvendorf, M. B., Kauppinen, S. (2021). Development of siRNA therapeutics for the treatment of liver diseases. Methods in Molecular Biology , 2282, 57–75;</Citation><ArticleIdList><ArticleId IdType="pubmed">33928570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, Y., Zhu, L., Wang, X., Jin, H. (2022). RNA-based therapeutics: An overview and prospectus. Cell Death &amp; Disease , 13(7), 644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9308039</ArticleId><ArticleId IdType="pubmed">35871216</ArticleId></ArticleIdList></Reference><Reference><Citation>Merck  (2024). Moderna and Merck announce mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA® (pembrolizumab), met primary efficacy endpoint in phase 2b KEYNOTE-942 trial. https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/
(accessed on 21/12/2023).</Citation></Reference><Reference><Citation>Saw, P. E., Song, E. (2024). Advancements in clinical RNA therapeutics: Present developments and prospective outlooks. Cell Reports Medicine , 5(5), 101555;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11148805</ArticleId><ArticleId IdType="pubmed">38744276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasso, J. M., Ambrose, B. J. B., Tenchov, R., Datta, R. S., Basel, M. T.et al. (2022). The progress and promise of RNA medicine—An arsenal of targeted treatments. Journal of Medicinal Chemistry , 65(10), 6975–7015;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115888</ArticleId><ArticleId IdType="pubmed">35533054</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey, M., Ojha, D., Bansal, S., Rode, A. B., Chawla, G. (2021). From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine , 81, 101003;</Citation><ArticleIdList><ArticleId IdType="pubmed">34332771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, Y. K. (2022). RNA therapy: Rich history, various applications and unlimited future prospects. Experimental &amp; Molecular Medicine , 54(4), 455–465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016686</ArticleId><ArticleId IdType="pubmed">35440755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, Y. K. (2020). RNA therapy: Current status and future potential. Chonnam Medical Journal , 56(2), 87–93;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250668</ArticleId><ArticleId IdType="pubmed">32509554</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard, A. J., Bijker, E. M. (2021). A guide to vaccinology: From basic principles to new developments. Nature Reviews Immunology , 21(2), 83–100;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Fayez, N., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A.et al. (2023). Recent advancement in mRNA vaccine development and applications. Pharmaceutics , 15(7), 1972. 10.3390/pharmaceutics15071972;</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15071972</ArticleId><ArticleId IdType="pmc">PMC10384963</ArticleId><ArticleId IdType="pubmed">37514158</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N., Hogan, M. J., Porter, F. W., Weissman, D. (2018). mRNA vaccines—A new era in vaccinology. Nature Reviews Drug Discovery , 17(4), 261–279. 10.1038/nrd.2017.243;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, Y., Duan, J., Yang, N., Yang, Y., Zhao, X. (2022). mRNA vaccines in the prevention and treatment of diseases. Medical Comminication , 3(3), e167. 10.1002/mco2.167;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.167</ArticleId><ArticleId IdType="pmc">PMC9409637</ArticleId><ArticleId IdType="pubmed">36033422</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q.et al. (2023). mRNA vaccine in cancer therapy: Current advance and future outlook. Clinical and Translational Medicine , 13(8), e1384. 10.1002/ctm2.1384;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.1384</ArticleId><ArticleId IdType="pmc">PMC10447885</ArticleId><ArticleId IdType="pubmed">37612832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorentzen, C. L., Haanen, J. B., Met, Ö., Svane, I. M. (2022). Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncology , 23(10), e450–e458. 10.1016/S1470-2045(22)00372-2;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(22)00372-2</ArticleId><ArticleId IdType="pmc">PMC9512276</ArticleId><ArticleId IdType="pubmed">36174631</ArticleId></ArticleIdList></Reference><Reference><Citation>Enokida, T., Moreira, A., Bhardwaj, N. (2021). Vaccines for immunoprevention of cancer. Journal of Clinical Investgation , 131(9), e146956;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087198</ArticleId><ArticleId IdType="pubmed">33938446</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, B., Pei, J., Xu, S., Liu, J., Yu, J. (2023). Recent advances in mRNA cancer vaccines: Meeting challenges and embracing opportunities. Frontiers in Immunology , 14, 1246682;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10511650</ArticleId><ArticleId IdType="pubmed">37744371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, G., Tang, T., Chen, Y., Huang, X., Liang, T. (2023). mRNA vaccines in disease prevention and treatment. Signal Transduction and Targeted Therapy , 8(1), 365;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10509165</ArticleId><ArticleId IdType="pubmed">37726283</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma, C., Pawar, V. A., Srivastava, S., Tyagi, A., Kaushik, G.et al. (2023). Cancer vaccines in the immunotherapy era: Promise and potential. Vaccines , 11(12), 1783;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10747700</ArticleId><ArticleId IdType="pubmed">38140187</ArticleId></ArticleIdList></Reference><Reference><Citation>Thara, E., Dorff, T. B., Pinski, J. K., Quinn, D. I. (2011). Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas , 69(4), 296–303;</Citation><ArticleIdList><ArticleId IdType="pubmed">21621934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiter, S., Diken, M., Selmi, A., Petschenka, J., Türeci, Ö.et al. (2016). FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines. Methods in Molecular Biology , 1428, 163–175;</Citation><ArticleIdList><ArticleId IdType="pubmed">27236799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., Bloom, F. E. (1992). Reversal of diabetes insipidus in Brattleboro rats: Intrahypothalamic injection of vasopressin mRNA. Science , 255(5047), 996–998;</Citation><ArticleIdList><ArticleId IdType="pubmed">1546298</ArticleId></ArticleIdList></Reference><Reference><Citation>Suschak, J. J., Williams, J. A., Schmaljohn, C. S. (2017). Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Human Vaccines &amp; Immunotherapeutics , 13(12), 2837–2848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718814</ArticleId><ArticleId IdType="pubmed">28604157</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandrup Schmidt, S., Foged, C., Korsholm, K. S., Rades, T., Christensen, D. (2016). Liposome-based adjuvants for subunit vaccines: Formulation strategies for subunit antigens and immunostimulators. Pharmaceutics , 8(1), 7;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810083</ArticleId><ArticleId IdType="pubmed">26978390</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H.et al. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy , 16(11), 1833–1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775451</ArticleId><ArticleId IdType="pubmed">18797453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauffman, K. J., Webber, M. J., Anderson, D. G. (2016). Materials for non-viral intracellular delivery of messenger RNA therapeutics. Journal of Controlled Release , 240, 227–234. 10.1016/j.jconrel.2015.12.032;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.12.032</ArticleId><ArticleId IdType="pubmed">26718856</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan, S., Rosenecker, J. (2017). Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Therapy , 24(3), 133–143. 10.1038/gt.2017.5;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2017.5</ArticleId><ArticleId IdType="pubmed">28094775</ArticleId></ArticleIdList></Reference><Reference><Citation>Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P.et al. (2015). Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Molecular Therapy , 23(9), 1456–1464. 10.1038/mt.2015.103;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2015.103</ArticleId><ArticleId IdType="pmc">PMC4817881</ArticleId><ArticleId IdType="pubmed">26050989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, S. C., Sekhon, S. S., Shin, W. R., Ahn, G., Cho, B. K.et al. (2022). Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Molecular &amp; Cellular Toxicology , 18(1), 1–8. 10.1007/s13273-021-00171-4;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13273-021-00171-4</ArticleId><ArticleId IdType="pmc">PMC8450916</ArticleId><ArticleId IdType="pubmed">34567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M.et al. (2015). Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Journal for Immunotherapy of Cancer , 3(1), 14. 10.1186/s40425-015-0055-3;</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-015-0055-3</ArticleId><ArticleId IdType="pmc">PMC4404644</ArticleId><ArticleId IdType="pubmed">25901286</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H.et al. (2017). Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature , 543(7644), 248–251. 10.1038/nature21428;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21428</ArticleId><ArticleId IdType="pmc">PMC5344708</ArticleId><ArticleId IdType="pubmed">28151488</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, W. F., Hung, C. H., Chai, C. Y., Hsu, K. F., He, L.et al. (2001). Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. Journal of Virology , 75(5), 2368–2376. 10.1128/JVI.75.5.2368-2376.2001;</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.5.2368-2376.2001</ArticleId><ArticleId IdType="pmc">PMC114820</ArticleId><ArticleId IdType="pubmed">11160740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljungberg, K., Liljeström, P. (2015). Self-replicating alphavirus RNA vaccines. Expert Review of Vaccines , 14(2), 177–194. 10.1586/14760584.2015.965690;</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.965690</ArticleId><ArticleId IdType="pubmed">25269775</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong, M., He, B., McAllister, W. T., Durbin, R. K. (1998). Promoter specificity determinants of T7 RNA polymerase. Proceedings of the National Academy of Sciences of the USA , 95(2), 515–519. 10.1073/pnas.95.2.515;</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.2.515</ArticleId><ArticleId IdType="pmc">PMC18451</ArticleId><ArticleId IdType="pubmed">9435223</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudzien-Nogalska, E., Stepinski, J., Jemielity, J., Zuberek, J., Stolarski, R.et al. (2007). Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability. Methods in Enzymology , 431, 203–227. 10.1016/S0076-6879(07)31011-2;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(07)31011-2</ArticleId><ArticleId IdType="pubmed">17923237</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, S. A., Moss, B. (1975). Modification of RNA by mRNA guanylyltransferase and mRNA (guanine-7-)methyltransferase from vaccinia virions. Journal of Biological Chemistry , 250(24), 9330–9335. 10.1016/S0021-9258(19)40647-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)40647-9</ArticleId><ArticleId IdType="pubmed">1194287</ArticleId></ArticleIdList></Reference><Reference><Citation>Habjan, M., Hubel, P., Lacerda, L., Benda, C., Holze, C.et al. (2013). Sequestration by IFIT1 impairs translation of 2′O-unmethylated capped RNA. PLoS Pathogens , 9(10), e1003663. 10.1371/journal.ppat.1003663;</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003663</ArticleId><ArticleId IdType="pmc">PMC3789756</ArticleId><ArticleId IdType="pubmed">24098121</ArticleId></ArticleIdList></Reference><Reference><Citation>Züst, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B. W.et al. (2011). Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nature Immunology , 12(2), 137–143. 10.1038/ni.1979;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1979</ArticleId><ArticleId IdType="pmc">PMC3182538</ArticleId><ArticleId IdType="pubmed">21217758</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstrohm, A. C., Wickens, M. (2008). Multifunctional deadenylase complexes diversify mRNA control. Nature Reviews Molecular Cell Biology , 9(4), 337–344. 10.1038/nrm2370;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2370</ArticleId><ArticleId IdType="pubmed">18334997</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima, S. A., Chipman, L. B., Nicholson, A. L., Chen, Y. H., Yee, B. A.et al. (2017). Short poly(A) tails are a conserved feature of highly expressed genes. Nature Structural &amp; Molecular Biology , 4(12), 1057–1063. 10.1038/nsmb.3499;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.3499</ArticleId><ArticleId IdType="pmc">PMC5877826</ArticleId><ArticleId IdType="pubmed">29106412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudla, G., Lipinski, L., Caffin, F., Helwak, A., Zylicz, M. (2006). High guanine and cytosine content increases mRNA levels in mammalian cells. Plos Biology , 4(6), e180. 10.1371/journal.pbio.0040180;</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0040180</ArticleId><ArticleId IdType="pmc">PMC1463026</ArticleId><ArticleId IdType="pubmed">16700628</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H.et al. (2010). Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Research , 38(17), 5884–5892. 10.1093/nar/gkq347;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq347</ArticleId><ArticleId IdType="pmc">PMC2943593</ArticleId><ArticleId IdType="pubmed">20457754</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N.et al. (2015). N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. Journal of Controlled Release , 217, 337–344. 10.1016/j.jconrel.2015.08.051;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.051</ArticleId><ArticleId IdType="pubmed">26342664</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman, D., Pardi, N., Muramatsu, H., Karikó, K. (2013). HPLC purification of in vitro transcribed long RNA. Methods in Molecular Biology , 969, 43–54. 10.1007/978-1-62703-260-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-260-5</ArticleId><ArticleId IdType="pubmed">23296926</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W.et al. (2020). Impact of mRNA chemistry and manufacturing process on innate immune activation. Science Advance , 6(26), eaaz6893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314518</ArticleId><ArticleId IdType="pubmed">32637598</ArticleId></ArticleIdList></Reference><Reference><Citation>Linares-Fernández, S., Lacroix, C., Exposito, J. Y., Verrier, B. (2020). Tailoring mRNA vaccine to balance Innate/Adaptive immune response. Trends in Molecular Medicine , 26(3), 311–323. 10.1016/j.molmed.2019.10.002;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2019.10.002</ArticleId><ArticleId IdType="pubmed">31699497</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulit-Penaloza, J. A., Scherbik, S. V., Brinton, M. A. (2012). Activation of Oas1a gene expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for Oas1b activation. Virology , 425(2), 71–81. 10.1016/j.virol.2011.11.025;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.11.025</ArticleId><ArticleId IdType="pmc">PMC3288655</ArticleId><ArticleId IdType="pubmed">22305621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, P., Sweeney, T. R., Skabkin, M. A., Skabkina, O. V., Hellen, C. U.et al. (2014). Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5′-terminal regions of cap0-, cap1- and 5′ppp- mRNAs. Nucleic Acids Research , 42(5), 3228–3245. 10.1093/nar/gkt1321;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1321</ArticleId><ArticleId IdType="pmc">PMC3950709</ArticleId><ArticleId IdType="pubmed">24371270</ArticleId></ArticleIdList></Reference><Reference><Citation>de Beuckelaer, A., Grooten, J., de Koker, S., (2017). Type I interferons modulate CD8+ T cell immunity to mRNA vaccines. Trends in Molecular Medicine , 23(3), 216–226. 10.1016/j.molmed.2017.01.006;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2017.01.006</ArticleId><ArticleId IdType="pubmed">28185789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C.et al. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature , 534(7607), 396–401. 10.1038/nature18300;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18300</ArticleId><ArticleId IdType="pubmed">27281205</ArticleId></ArticleIdList></Reference><Reference><Citation>Broos, K., van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C.et al. (2016). Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon. Molecular Therapy Nucleic Acids , 5(6), e326. 10.1038/mtna.2016.38;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2016.38</ArticleId><ArticleId IdType="pmc">PMC5022130</ArticleId><ArticleId IdType="pubmed">27327138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng, C., Zhang, C., Walker, P. G., Dong, Y. (2022). Formulation and delivery technologies for mRNA vaccines. Current Topics in Microbiology Immunology , 440, 71–110;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195316</ArticleId><ArticleId IdType="pubmed">32483657</ArticleId></ArticleIdList></Reference><Reference><Citation>Phua, K. K., Staats, H. F., Leong, K. W., Nair, S. K. (2014). Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Scientific Reports , 4(1), 5128. 10.1038/srep05128;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep05128</ArticleId><ArticleId IdType="pmc">PMC4044635</ArticleId><ArticleId IdType="pubmed">24894817</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C.et al. (2016). Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. Journal of Virology , 90(1), 332–344. 10.1128/JVI.01786-15;</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01786-15</ArticleId><ArticleId IdType="pmc">PMC4702536</ArticleId><ArticleId IdType="pubmed">26468547</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T.et al. (2014). A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Molecular Therapy , 22(12), 2118–2129. 10.1038/mt.2014.133;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.133</ArticleId><ArticleId IdType="pmc">PMC4429691</ArticleId><ArticleId IdType="pubmed">25027661</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogers, W. M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E. J.et al. (2015). Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. The Journal of Infectious Diseases , 211(6), 947–955;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416123</ArticleId><ArticleId IdType="pubmed">25234719</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruggi, G., Chiarot, E., Giovani, C., Buccato, S., Bonacci, S.et al. (2017). Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine , 35(2), 361–368;</Citation><ArticleIdList><ArticleId IdType="pubmed">27939014</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C.et al. (2015). Self-amplifying mRNA vaccines. Advances in Genetics , 89, 179–233;</Citation><ArticleIdList><ArticleId IdType="pubmed">25620012</ArticleId></ArticleIdList></Reference><Reference><Citation>Perche, F., Benvegnu, T., Berchel, M., Lebegue, L., Pichon, C.et al. (2011). Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine , 7(4), 445–453;</Citation><ArticleIdList><ArticleId IdType="pubmed">21220051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockey, M., Bourseau, E., Chandrashekhar, V., Chaudhuri, A., Lafosse, S.et al. (2007). mRNA-based cancer vaccine: Prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Therapy , 14(9), 802–814;</Citation><ArticleIdList><ArticleId IdType="pubmed">17589432</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida, S., Kinoh, H., Ishii, T., Matsui, A., Tockary, T. A.et al. (2016). Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials , 82, 221–228;</Citation><ArticleIdList><ArticleId IdType="pubmed">26763736</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard, C., Rejman, J., de Haes, W., Verrier, B., van Gulck, E., et al. (2013). Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Molecular Therapy , 21(1), 251–259;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538310</ArticleId><ArticleId IdType="pubmed">23011030</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E.et al. (1993). Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. European Journal of Immunology , 23(7), 1719–1722;</Citation><ArticleIdList><ArticleId IdType="pubmed">8325342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, W. Z., Hoon, D. S., Huang, S. K., Fujii, S., Hashimoto, K.et al. (1999). RNA melanoma vaccine: Induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Human Gene Therapy , 10(16), 2719–2724;</Citation><ArticleIdList><ArticleId IdType="pubmed">10566900</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V.et al. (2017). Modified mRNA vaccines protect against Zika virus infection. Cell , 168(6), 1114–25.e10;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388441</ArticleId><ArticleId IdType="pubmed">28222903</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A.et al. (2017). Vaccine mediated protection against zika virus-induced congenital disease. Cell , 170(2), 273–83.e12. 10.1016/j.cell.2017.06.040;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.06.040</ArticleId><ArticleId IdType="pmc">PMC5546158</ArticleId><ArticleId IdType="pubmed">28708997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A.et al. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Molecular Therapy , 25(6), 1316–1327. 10.1016/j.ymthe.2017.03.035;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.03.035</ArticleId><ArticleId IdType="pmc">PMC5475249</ArticleId><ArticleId IdType="pubmed">28457665</ArticleId></ArticleIdList></Reference><Reference><Citation>Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R.et al. (2016). Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS One , 11(8), e0161193. 10.1371/journal.pone.0161193;</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0161193</ArticleId><ArticleId IdType="pmc">PMC4985159</ArticleId><ArticleId IdType="pubmed">27525409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hekele, A., Bertholet, S., Archer, J., Gibson, D. G., Palladino, G.et al. (2013). Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerging Microbes &amp; Infections , 2(8), e52. 10.1038/emi.2013.54;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2013.54</ArticleId><ArticleId IdType="pmc">PMC3821287</ArticleId><ArticleId IdType="pubmed">26038486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzaro, S., Giovani, C., Mangiavacchi, S., Magini, D., Maione, D.et al. (2015). CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology , 146(2), 312–326. 10.1111/imm.12505;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12505</ArticleId><ArticleId IdType="pmc">PMC4582972</ArticleId><ArticleId IdType="pubmed">26173587</ArticleId></ArticleIdList></Reference><Reference><Citation>Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A.et al. (2012). Nonviral delivery of self-amplifying RNA vaccines. Proceedings of the National Academy of Sciences of the USA , 109(36), 14604–14609. 10.1073/pnas.1209367109;</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1209367109</ArticleId><ArticleId IdType="pmc">PMC3437863</ArticleId><ArticleId IdType="pubmed">22908294</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S.et al. (2017). Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Letters , 17(3), 1326–1335. 10.1021/acs.nanolett.6b03329;</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.6b03329</ArticleId><ArticleId IdType="pmc">PMC5523404</ArticleId><ArticleId IdType="pubmed">28273716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K.et al. (2016). Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and toxoplasma gondii challenges with a single dose. Proceedings of the National Academy of Sciences of the USA , 113(29), E4133–E4142. 10.1073/pnas.1600299113;</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1600299113</ArticleId><ArticleId IdType="pmc">PMC4961123</ArticleId><ArticleId IdType="pubmed">27382155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahal, J. S., Fang, T., Woodham, A. W., Khan, O. F., Ling, J.et al. (2017). An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Scientific Reports , 7(1), 252. 10.1038/s41598-017-00193-w;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00193-w</ArticleId><ArticleId IdType="pmc">PMC5427874</ArticleId><ArticleId IdType="pubmed">28325910</ArticleId></ArticleIdList></Reference><Reference><Citation>Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B.et al. (2012). Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nature Biotechnology , 30(12), 1210–1216. 10.1038/nbt.2436;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2436</ArticleId><ArticleId IdType="pubmed">23159882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallen, K. J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T.et al. (2013). A novel, disruptive vaccination technology: Self-adjuvanted RNActive® vaccines. Human Vaccines &amp; Immunotherapeutics , 9(10), 2263–2276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906413</ArticleId><ArticleId IdType="pubmed">23921513</ArticleId></ArticleIdList></Reference><Reference><Citation>Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A.et al. (2009). Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. Journal of Immunotherapy , 32(5), 498–507;</Citation><ArticleIdList><ArticleId IdType="pubmed">19609242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastian, M., Papachristofilou, A., Weiss, C., Früh, M., Cathomas, R.et al. (2014). Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine RNActive® combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer , 14, 748;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4195907</ArticleId><ArticleId IdType="pubmed">25288198</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S.et al. (2011). Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. Journal of Immunotherapy , 34(1), 1–15;</Citation><ArticleIdList><ArticleId IdType="pubmed">21150709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W.et al. (2015). Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: A first-in-man phase I/IIa study. Journal for Immunotherapy of Cancer , 3, 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468959</ArticleId><ArticleId IdType="pubmed">26082837</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P.et al. (2016). An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Neglected Tropical Diseases , 10(6), e0004746;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918980</ArticleId><ArticleId IdType="pubmed">27336830</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotin-Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Kowalczyk, A.et al. (2014). mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiation Oncology , 9, 180;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4150951</ArticleId><ArticleId IdType="pubmed">25127546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Su, H. H., Yang, Y., Hu, Y., Zhang, L.et al. (2013). Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Molecular Therapy , 21(2), 358–367;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3594035</ArticleId><ArticleId IdType="pubmed">23229091</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough, K. C., Bassi, I., Milona, P., Suter, R., Thomann-Harwood, L.et al. (2014). Self-replicating Replicon-RNA delivery to dendritic cells by chitosan-nanoparticles for translation in Vitro and in Vivo. Molecular Therapy Nucleic Acids , 3(7), e173;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4121514</ArticleId><ArticleId IdType="pubmed">25004099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wykes, M., Pombo, A., Jenkins, C., MacPherson, G. G. (1998). Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. Journal of Immunology , 161(3), 1313–1319.</Citation><ArticleIdList><ArticleId IdType="pubmed">9686593</ArticleId></ArticleIdList></Reference><Reference><Citation>Selmi, A., Vascotto, F., Kautz-Neu, K., Türeci, Ö., Sahin, U.et al. (2016). Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunology, Immunotherapy , 65(9), 1075–1083;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11028682</ArticleId><ArticleId IdType="pubmed">27422115</ArticleId></ArticleIdList></Reference><Reference><Citation>Diken, M., Kreiter, S., Selmi, A., Britten, C. M., Huber, C.et al. (2011). Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Therapy , 18(7), 702–708;</Citation><ArticleIdList><ArticleId IdType="pubmed">21368901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz, C., Fotin-Mleczek, M., Roth, G., Becker, C., Dam, T. C.et al. (2011). Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biology , 8(4), 627–636;</Citation><ArticleIdList><ArticleId IdType="pubmed">21654214</ArticleId></ArticleIdList></Reference><Reference><Citation>Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., Breckpot, K. (2015). mRNA-based dendritic cell vaccines. Expert Review of Vaccines , 14(2), 161–176;</Citation><ArticleIdList><ArticleId IdType="pubmed">25196947</ArticleId></ArticleIdList></Reference><Reference><Citation>Granstein, R. D., Ding, W., Ozawa, H. (2000). Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. The Journal of Investigative Dermatology , 114(4), 632–636;</Citation><ArticleIdList><ArticleId IdType="pubmed">10733665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M.et al. (2010). Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Research , 70(22), 9031–9040. 10.1158/0008-5472.CAN-10-0699;</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-10-0699</ArticleId><ArticleId IdType="pubmed">21045153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialkowski, L., van Weijnen, A., van der Jeught, K., Renmans, D., Daszkiewicz, L.et al. (2016). Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Scientific Reports , 6(1), 22509. 10.1038/srep22509;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22509</ArticleId><ArticleId IdType="pmc">PMC4773884</ArticleId><ArticleId IdType="pubmed">26931556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin, U., Derhovanessian, E., Miller, M., Kloke, B. P., Simon, P.et al. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature , 547(7662), 222–226. 10.1038/nature23003;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23003</ArticleId><ArticleId IdType="pubmed">28678784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, X., Zaks, T., Langer, R., Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Review Materials , 6(12), 1078–1094. 10.1038/s41578-021-00358-0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00358-0</ArticleId><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu, P., Ziegelhoffer, P., Sun, J., Yang, N. S. (1996). Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Therapy , 3(3), 262–268;</Citation><ArticleIdList><ArticleId IdType="pubmed">8646558</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson, D. X., Ljungberg, K., Kakoulidou, M., Liljeström, P. (2012). Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One , 7(1), e29732. 10.1371/journal.pone.0029732;</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029732</ArticleId><ArticleId IdType="pmc">PMC3251598</ArticleId><ArticleId IdType="pubmed">22238645</ArticleId></ArticleIdList></Reference><Reference><Citation>Piggott, J. M., Sheahan, B. J., Soden, D. M., O’Sullivan, G. C., Atkins, G. J. (2009). Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Molecular Medicine Reports , 2(5), 753–756;</Citation><ArticleIdList><ArticleId IdType="pubmed">21475897</ArticleId></ArticleIdList></Reference><Reference><Citation>Broderick, K. E., Humeau, L. M. (2015). Electroporation-enhanced delivery of nucleic acid vaccines. Expert Review of Vaccines , 14(2), 195–204. 10.1586/14760584.2015.990890;</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.990890</ArticleId><ArticleId IdType="pubmed">25487734</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlake, T., Thess, A., Fotin-Mleczek, M., Kallen, K. J. (2012). Developing mRNA-vaccine technologies. RNA Biology , 9(11), 1319–1330. 10.4161/rna.22269;</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rna.22269</ArticleId><ArticleId IdType="pmc">PMC3597572</ArticleId><ArticleId IdType="pubmed">23064118</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó, K., Muramatsu, H., Ludwig, J., Weissman, D. (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Research , 39(21), e142. 10.1093/nar/gkr695;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr695</ArticleId><ArticleId IdType="pmc">PMC3241667</ArticleId><ArticleId IdType="pubmed">21890902</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. Therapeutic Delivery , 7(5), 319–334. 10.4155/tde-2016-0006;</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde-2016-0006</ArticleId><ArticleId IdType="pmc">PMC5439223</ArticleId><ArticleId IdType="pubmed">27075952</ArticleId></ArticleIdList></Reference><Reference><Citation>Midoux, P., Pichon, C. (2015). Lipid-based mRNA vaccine delivery systems. Expert Review of Vaccines , 14(2), 221–234. 10.1586/14760584.2015.986104;</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.986104</ArticleId><ArticleId IdType="pubmed">25540984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanasty, R., Dorkin, J. R., Vegas, A., Anderson, D. (2013). Delivery materials for siRNA therapeutics. Nature Materials , 12(11), 967–977. 10.1038/nmat3765;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmat3765</ArticleId><ArticleId IdType="pubmed">24150415</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M.et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Molecular Therapy , 18(7), 1357–1364. 10.1038/mt.2010.85;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.85</ArticleId><ArticleId IdType="pmc">PMC2911264</ArticleId><ArticleId IdType="pubmed">20461061</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L.et al. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release , 217, 345–351. 10.1016/j.jconrel.2015.08.007;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.007</ArticleId><ArticleId IdType="pmc">PMC4624045</ArticleId><ArticleId IdType="pubmed">26264835</ArticleId></ArticleIdList></Reference><Reference><Citation>Havenar-Daughton, C., Lee, J. H., Crotty, S. (2017). Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunological Reviews , 275(1), 49–61. 10.1111/imr.12512;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12512</ArticleId><ArticleId IdType="pubmed">28133798</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam, H. H., Melo, M. B., Kang, M., Pelet, J. M., Ruda, V. M.et al. (2016). Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proceedings of the National Academy of Sciences of the USA , 113(43), E6639–e6648. 10.1073/pnas.1606050113;</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1606050113</ArticleId><ArticleId IdType="pmc">PMC5086995</ArticleId><ArticleId IdType="pubmed">27702895</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmer, J. B., Geall, A. J. (2016). Recent innovations in mRNA vaccines. Current Opinion in Immunology , 41, 18–22. 10.1016/j.coi.2016.05.008;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2016.05.008</ArticleId><ArticleId IdType="pubmed">27240054</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigneron, N. (2015). Human tumor antigens and cancer immunotherapy. BioMed Research International , 2015(12), 948501. 10.1155/2015/948501;</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/948501</ArticleId><ArticleId IdType="pmc">PMC4487697</ArticleId><ArticleId IdType="pubmed">26161423</ArticleId></ArticleIdList></Reference><Reference><Citation>Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C.et al. (2016). Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clinical Cancer Research , 22(8), 1885–1896. 10.1158/1078-0432.CCR-15-1509;</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1509</ArticleId><ArticleId IdType="pubmed">27084742</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulie, P. G., van den Eynde, B. J., van der Bruggen, P., Boon, T. (2014). Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nature Reviews Cancer , 14(2), 135–146;</Citation><ArticleIdList><ArticleId IdType="pubmed">24457417</ArticleId></ArticleIdList></Reference><Reference><Citation>Conry, R. M., LoBuglio, A. F., Wright, M., Sumerel, L., Pike, M. J.et al. (1995). Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Research , 55(7), 1397–1400;</Citation><ArticleIdList><ArticleId IdType="pubmed">7882341</ArticleId></ArticleIdList></Reference><Reference><Citation>Boczkowski, D., Nair, S. K., Snyder, D., Gilboa, E. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. The Journal of Experimental Medicine , 184(2), 465–472;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192710</ArticleId><ArticleId IdType="pubmed">8760800</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarntzen, E. H., Schreibelt, G., Bol, K., Lesterhuis, W. J., Croockewit, A. J.et al. (2012). Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clinical Cancer Research , 18(19), 5460–5470;</Citation><ArticleIdList><ArticleId IdType="pubmed">22896657</ArticleId></ArticleIdList></Reference><Reference><Citation>van Driessche, A., van de Velde, A. L., Nijs, G., Braeckman, T., Stein, B.et al. (2009). Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy , 11(5), 653–668;</Citation><ArticleIdList><ArticleId IdType="pubmed">19530029</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tendeloo, V. F., van de Velde, A., van Driessche, A., Cools, N., Anguille, S.et al. (2010). Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Sciences of the USA , 107(31), 13824–13829. 10.1073/pnas.1008051107;</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008051107</ArticleId><ArticleId IdType="pmc">PMC2922237</ArticleId><ArticleId IdType="pubmed">20631300</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury, H. J., Collins, Jr. R. H., Blum, W., Stiff, P. S., Elias, L.et al. (2017). Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer , 123(16), 3061–3072. 10.1002/cncr.30696;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30696</ArticleId><ArticleId IdType="pubmed">28411378</ArticleId></ArticleIdList></Reference><Reference><Citation>Rausch, S., Schwentner, C., Stenzl, A., Bedke, J. (2014). mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Human Vaccines &amp; Immunotherapeutics , 10(11), 3146–3152. 10.4161/hv.29553;</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.29553</ArticleId><ArticleId IdType="pmc">PMC4514038</ArticleId><ArticleId IdType="pubmed">25483661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell, D. A., Cui, X., Schmittling, R. J., Sanchez-Perez, L., Snyder, D. J.et al. (2011). Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood , 118(11), 3003–3012. 10.1182/blood-2011-02-334565;</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-02-334565</ArticleId><ArticleId IdType="pmc">PMC3175779</ArticleId><ArticleId IdType="pubmed">21768296</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M. N., Sanchez-Perez, L.et al. (2015). Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature , 519(7543), 366–369. 10.1038/nature14320;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14320</ArticleId><ArticleId IdType="pmc">PMC4510871</ArticleId><ArticleId IdType="pubmed">25762141</ArticleId></ArticleIdList></Reference><Reference><Citation>Batich, K. A., Reap, E. A., Archer, G. E., Sanchez-Perez, L., Nair, S. K.et al. (2017). Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clinical Cancer Research , 23(8), 1898–1909. 10.1158/1078-0432.CCR-16-2057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2057</ArticleId><ArticleId IdType="pmc">PMC5559300</ArticleId><ArticleId IdType="pubmed">28411277</ArticleId></ArticleIdList></Reference><Reference><Citation>Borch, T. H., Engell-Noerregaard, L., Zeeberg Iversen, T., Ellebaek, E., Met, Ö.et al. (2016). mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology , 5(9), e1207842. 10.1080/2162402X.2016.1207842;</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2016.1207842</ArticleId><ArticleId IdType="pmc">PMC5048758</ArticleId><ArticleId IdType="pubmed">27757300</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen, B. E., Stoitzner, P. (2015). Functional specialization of skin dendritic cell subsets in regulating T cell responses. Frontiers in Immunology , 6(6), 534. 10.3389/fimmu.2015.00534;</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00534</ArticleId><ArticleId IdType="pmc">PMC4617171</ArticleId><ArticleId IdType="pubmed">26557117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyte, J. A., Aamdal, S., Dueland, S., Sæbøe-Larsen, S., Inderberg, E. M.et al. (2016). Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology , 5(11), e1232237. 10.1080/2162402X.2016.1232237;</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2016.1232237</ArticleId><ArticleId IdType="pmc">PMC5139630</ArticleId><ArticleId IdType="pubmed">27999747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vik-Mo, E. O., Nyakas, M., Mikkelsen, B. V., Moe, M. C., Due-Tønnesen, P.et al. (2013). Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunology, Immunotherapy , 62(9), 1499–1509. 10.1007/s00262-013-1453-3;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-013-1453-3</ArticleId><ArticleId IdType="pmc">PMC3755221</ArticleId><ArticleId IdType="pubmed">23817721</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilgenhof, S., van Nuffel, A. M. T., Benteyn, D., Corthals, J., Aerts, C.et al. (2013). A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Annals of Oncology , 24(10), 2686–2693. 10.1093/annonc/mdt245;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdt245</ArticleId><ArticleId IdType="pubmed">23904461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S.et al. (2016). Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. Journal of Clinical Oncology , 34(12), 1330–1338. 10.1200/JCO.2015.63.4121;</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.63.4121</ArticleId><ArticleId IdType="pubmed">26926680</ArticleId></ArticleIdList></Reference><Reference><Citation>Weide, B., Carralot, J. P., Reese, A., Scheel, B., Eigentler, T. K.et al. (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Journal of Immunotherapy , 31(2), 180–188. 10.1097/CJI.0b013e31815ce501;</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CJI.0b013e31815ce501</ArticleId><ArticleId IdType="pubmed">18481387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesterhuis, W. J., De Vries, I. J., Schreibelt, G., Schuurhuis, D. H., Aarntzen, E. H.et al. (2010). Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Research , 30(12), 5091–5097;</Citation><ArticleIdList><ArticleId IdType="pubmed">21187495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol, K. F., Mensink, H. W., Aarntzen, E. H., Schreibelt, G., Keunen, J. E.et al. (2014). Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. American Journal of Ophthalmology , 158(5), 939–947. 10.1016/j.ajo.2014.07.014;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2014.07.014</ArticleId><ArticleId IdType="pubmed">25038326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol, K. F., Aarntzen, E. H., Pots, J. M., Olde Nordkamp, M. A., van de Rakt, M. W., et al. (2016). Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunology, Immunotherapy , 65(3), 327–339;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779136</ArticleId><ArticleId IdType="pubmed">26861670</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol, K. F., Figdor, C. G., Aarntzen, E. H., Welzen, M. E., van Rossum, M. M., et al. (2015). Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology , 4(8), e1019197;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4570143</ArticleId><ArticleId IdType="pubmed">26405571</ArticleId></ArticleIdList></Reference><Reference><Citation>De Keersmaecker, B., Heirman, C., Corthals, J., Empsen, C., van Grunsven, L. A., et al. (2011). The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. Journal of Leukocyte Biology , 89(6), 989–999;</Citation><ArticleIdList><ArticleId IdType="pubmed">21427207</ArticleId></ArticleIdList></Reference><Reference><Citation>Dannull, J., Nair, S., Su, Z., Boczkowski, D., DeBeck, C.et al. (2005). Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood , 105(8), 3206–3213;</Citation><ArticleIdList><ArticleId IdType="pubmed">15618466</ArticleId></ArticleIdList></Reference><Reference><Citation>Aerts-Toegaert, C., Heirman, C., Tuyaerts, S., Corthals, J., Aerts, J. L.et al. (2007). CD83 expression on dendritic cells and T cells: Correlation with effective immune responses. European Journal of Immunology , 37(3), 686–695;</Citation><ArticleIdList><ArticleId IdType="pubmed">17301951</ArticleId></ArticleIdList></Reference><Reference><Citation>Grünebach, F., Kayser, K., Weck, M. M., Müller, M. R., Appel, S.et al. (2005). Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Therapy , 12(9), 749–756. 10.1038/sj.cgt.7700842;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cgt.7700842</ArticleId><ArticleId IdType="pubmed">15877082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bontkes, H. J., Kramer, D., Ruizendaal, J. J., Meijer, C. J., Hooijberg, E. (2008). Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clinical Immunology , 127(3), 375–384. 10.1016/j.clim.2008.02.001;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.02.001</ArticleId><ArticleId IdType="pubmed">18358784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bontkes, H. J., Kramer, D., Ruizendaal, J. J., Kueter, E. W., van Tendeloo, V. F., et al. (2007). Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Therapy , 14(4), 366–375. 10.1038/sj.gt.3302874;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3302874</ArticleId><ArticleId IdType="pubmed">17036057</ArticleId></ArticleIdList></Reference><Reference><Citation>Dörrie, J., Schaft, N., Müller, I., Wellner, V., Schunder, T.et al. (2008). Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunology, Immunotherapy , 57(4), 467–477. 10.1007/s00262-007-0385-1;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-007-0385-1</ArticleId><ArticleId IdType="pmc">PMC11041385</ArticleId><ArticleId IdType="pubmed">17768622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonehill, A., Tuyaerts, S., Van Nuffel, A. M., Heirman, C., Bos, T. J.et al. (2008). Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Molecular Therapy , 16(6), 1170–1180. 10.1038/mt.2008.77;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.77</ArticleId><ArticleId IdType="pubmed">18431362</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lint, S., Goyvaerts, C., Maenhout, S., Goethals, L., Disy, A.et al. (2012). Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Research , 72(7), 1661–1671;</Citation><ArticleIdList><ArticleId IdType="pubmed">22337996</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lint, S., Wilgenhof, S., Heirman, C., Corthals, J., Breckpot, K.et al. (2014). Optimized dendritic cell-based immunotherapy for melanoma: The TriMix-formula. Cancer Immunology, Immunotherapy , 63(9), 959–967;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11029216</ArticleId><ArticleId IdType="pubmed">24878889</ArticleId></ArticleIdList></Reference><Reference><Citation>Pen, J. J., De Keersmaecker, B., Maenhout, S. K., Van Nuffel, A. M., Heirman, C.et al. (2013). Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. Journal of Immunology , 191(4), 1976–1983.</Citation><ArticleIdList><ArticleId IdType="pubmed">23842750</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilgenhof, S., van Nuffel, A. M., Corthals, J., Heirman, C., Tuyaerts, S.et al. (2011). Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. Journal of Immunotherapy , 34(5), 448–456;</Citation><ArticleIdList><ArticleId IdType="pubmed">21577140</ArticleId></ArticleIdList></Reference><Reference><Citation>Chehelgerdi, M., Chehelgerdi, M. (2023). The use of RNA-based treatments in the field of cancer immunotherapy. Molecular Cancer , 22(1), 106;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10401791</ArticleId><ArticleId IdType="pubmed">37420174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiter, S., Diken, M., Selmi, A., Diekmann, J., Attig, S.et al. (2011). FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Research , 71(19), 6132–6142. 10.1158/0008-5472.CAN-11-0291;</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-11-0291</ArticleId><ArticleId IdType="pubmed">21816907</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheel, B., Aulwurm, S., Probst, J., Stitz, L., Hoerr, I.et al. (2006). Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. European Journal of Immunology , 36(10), 2807–2816. 10.1002/eji.200635910;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200635910</ArticleId><ArticleId IdType="pubmed">17013976</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Jeught, K., Joe, P. T., Bialkowski, L., Heirman, C., Daszkiewicz, L.et al. (2014). Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget , 5(20), 10100–10113. 10.18632/oncotarget.2463;</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.2463</ArticleId><ArticleId IdType="pmc">PMC4259408</ArticleId><ArticleId IdType="pubmed">25338019</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lint, S., Renmans, D., Broos, K., Goethals, L., Maenhout, S.et al. (2016). Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunology Research , 4(2), 146–156. 10.1158/2326-6066.CIR-15-0163;</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0163</ArticleId><ArticleId IdType="pubmed">26659303</ArticleId></ArticleIdList></Reference><Reference><Citation>Muralidhara, B. K., Baid, R., Bishop, S. M., Huang, M., Wang, W.et al. (2016). Critical considerations for developing nucleic acid macromolecule based drug products. Drug Discovery Today , 21(3), 430–444. 10.1016/j.drudis.2015.11.012;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2015.11.012</ArticleId><ArticleId IdType="pubmed">26674130</ArticleId></ArticleIdList></Reference><Reference><Citation>Said, S. S., Ibrahim, W. N. (2023). Cancer resistance to immunotherapy: Comprehensive insights with future perspectives. Pharmaceutics , 15(4), 1143;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10141036</ArticleId><ArticleId IdType="pubmed">37111629</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W.et al. (2023). Therapeutic cancer vaccines: Advancements, challenges, and prospects. Signal Transduction and Targeted Therapy , 8(1), 450;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10716479</ArticleId><ArticleId IdType="pubmed">38086815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I.et al. (2022). Cancer vaccines: The next immunotherapy frontier. Nature Cancer , 3(8), 911–926;</Citation><ArticleIdList><ArticleId IdType="pubmed">35999309</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, I., Chen, M. Y., Goedegebuure, S. P., Gillanders, W. E. (2021). Challenges targeting cancer neoantigens in 2021: A systematic literature review. Expert Review of Vaccines , 20(7), 827–837;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410655</ArticleId><ArticleId IdType="pubmed">34047245</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, K.-C., Park, D., Ju, S., Lee, Y. E., Heo, S.-H.et al. (2020). Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging. Scientific Reports , 10(1), 5885;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125174</ArticleId><ArticleId IdType="pubmed">32245999</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z.et al. (2024). Immunomodulatory precision: A narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment. International Journal of Molecular Science , 25(10), 5490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11122264</ArticleId><ArticleId IdType="pubmed">38791528</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao, L., Wang, Q., Ma, W. (2023). Navigating the immune maze: Pioneering strategies for unshackling cancer immunotherapy resistance. Cancers , 15(24), 5857;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10742031</ArticleId><ArticleId IdType="pubmed">38136402</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., Marques, M. P. C. (2021). mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine , 39(16), 2190–2200;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987532</ArticleId><ArticleId IdType="pubmed">33771389</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary, N., Weissman, D., Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. Nature Reviews Drug Discovery , 20(11), 817–838;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8386155</ArticleId><ArticleId IdType="pubmed">34433919</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, M. A. (2010). Immunologic basis of vaccine vectors. Immunity , 33(4), 504–515;</Citation><ArticleIdList><ArticleId IdType="pubmed">21029961</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, B., Jeang, J., Yang, A., Wu, T. C., Hung, C. F. (2014). DNA vaccine for cancer immunotherapy. Human Vaccines &amp; Immunotherapeutics , 10(11), 3153–3164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514137</ArticleId><ArticleId IdType="pubmed">25625927</ArticleId></ArticleIdList></Reference><Reference><Citation>Flemming, A. (2012). Vaccines: Self-amplifying RNA in lipid nanoparticles: A next-generation vaccine? Nature Reviews Drug Discovery , 11(10), 748–749;</Citation><ArticleIdList><ArticleId IdType="pubmed">23023675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer, G. (2010). RNA replicons-a new approach for influenza virus immunoprophylaxis. Viruses , 2(2), 413–434;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185613</ArticleId><ArticleId IdType="pubmed">21994644</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, Y., Lei, K., Tang, L. (2018). Neoantigen vaccine delivery for personalized anticancer immunotherapy. Frontiers in Immunology , 9, 1499;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6036114</ArticleId><ArticleId IdType="pubmed">30013560</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa, E., Lérias, J. R., Beltran, A., Paraschoudi, G., Condeço, C.et al. (2021). Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery. Frontiers in Immunology , 12, 592031;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8320363</ArticleId><ArticleId IdType="pubmed">34335558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemesh, C. S., Hsu, J. C., Hosseini, I., Shen, B. Q., Rotte, A.et al. (2021). Personalized cancer vaccines: Clinical landscape, challenges, and opportunities. Molecular Therapy , 29(2), 555–570. 10.1016/j.ymthe.2020.09.038;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7854282</ArticleId><ArticleId IdType="pubmed">33038322</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambridge, M., Kenilworth, N. J.
(2018). Moderna and merck expand mRNA cancer vaccines collaboration. https://www.merck.com/news/moderna-and-merck-expand-mrna-cancer-vaccines-collaboration/
(accessed on 21/12/2023).</Citation></Reference><Reference><Citation>BioNTech, I. (2021). BioNTech receives FDA fast track designation for its FixVac candidate BNT111 in advanced melanoma. https://investors.biontech.de/news-releases/news-release-details/biontech-receives-fda-fast-track-designation-its-fixvac
(accessed on 21/12/2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>